MUL 1867

Drug Profile

MUL 1867

Alternative Names: MUL-1867-CF

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TGV-Laboratories
  • Developer TGV Therapeutics; TGV-Laboratories
  • Class Antibacterials; Antibronchitics; Hydrazines
  • Mechanism of Action Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Gingivitis; Periodontitis
  • Clinical Phase Unknown Cystic fibrosis; Pneumonia
  • Preclinical Burn infections; Conjunctivitis; Diabetic foot ulcer; Emphysema; Lung disorders; Skin and soft tissue infections; Vaginitis
  • Research Nosocomial pneumonia
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 10 Aug 2018 Clinical development in Cystic fibrosis is ongoing in Russia (Inhalation) (TGV Laboratories pipeline, August 2018)
  • 10 Aug 2018 Discontinued - Clinical-Phase-Unknown for Chronic obstructive pulmonary disease in Russia (Inhalation)
  • 10 Aug 2018 Preclinical trials in Cystic fibrosis in USA (Inhalation) (TGV Laboratories pipeline, August 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top